Table 3.
Univariate and multivariate analyses of PFS in patients
| Characteristic | Before PSM | After PSM | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||||||
| HR | 95%CI | P | HR | 95%CI | P | HR | 95% CI | P | HR | 95% CI | P | ||
| Age (years) | ≤60/ >60 | 1.142 | 0.572‐2.279 | .707 | NI | 0.927 | 0.457‐1.884 | .835 | NI | ||||
| Gender | Female/ Male | 1.448 | 0.722‐2.902 | .297 | NI | 1.650 | 0.803‐3.390 | .173 | NI | ||||
| Tumor size (cm) | ≤2/ 2 ~ 4/ >4 | 0.950 | 0.497‐1.815 | .876 | NI | 1.141 | 0.587‐2.215 | .697 | NI | ||||
| Tumor grade | Well/ Moderate/ Poor | 1.232 | 0.691‐2.199 | .480 | NI | 1.098 | 0.619‐1.950 | .749 | NI | ||||
| LN metastasis | Absent/ Present | 1.434 | 0.645‐3.189 | .376 | NI | 1.444 | 0.646‐3.226 | .370 | NI | ||||
| Tumor site | Head/ Body/ Tail | 0.973 | 0.613‐1.545 | .909 | NI | 1.077 | 0.653‐1.776 | .771 | NI | ||||
| WBC (*109) | ≤10/ >10 | 1.560 | 0.592‐4.109 | .369 | NI | 1.542 | 0.583‐4.078 | .383 | NI | ||||
| HGB (g/L) | ≤120/ >120 | 0.515 | 0.122‐2.180 | .367 | NI | 0.520 | 0.122‐2.205 | 0.375 | NI | ||||
| PLT (*109) | ≤300/ >300 | 0.434 | 0.132‐1.427 | .169 | NI | 0.604 | 0.181‐2.011 | .411 | NI | ||||
| ALT (U/L) | ≤40/ >40 | 0.800 | 0.380‐1.683 | .557 | NI | 0.832 | 0.384‐1.803 | .642 | NI | ||||
| AST (U/L) | ≤40/ >40 | 1.275 | 0.553‐2.943 | .569 | NI | 1.025 | 0.421‐2.495 | .956 | NI | ||||
| ALP (U/L) | ≤100/ >100 | 0.578 | 0.284‐1.175 | .130 | NI | 0.578 | 0.279‐1.200 | .142 | NI | ||||
| GGT (U/L) | ≤45/ >45 | 0.606 | 0.300‐1.225 | .163 | NI | 0.635 | 0.309‐1.303 | .216 | NI | ||||
| ALB (g/L) | ≤40/ >40 | 0.392 | 0.165‐0.930 | .034 | 0.372 | 0.156‐0.888 | 0.026 | 0.471 | 0.189‐1.175 | .107 | NI | ||
| TBIL (µmol/L) | ≤20.5/ >20.5 | 0.594 | 0.243‐1.453 | .254 | NI | 0.544 | 0.220‐1.345 | .187 | NI | ||||
| IBIL (µmol/L) | ≤ 5/ >15 | 1.580 | 0.603‐4.137 | .352 | NI | 1.556 | 0.592‐4.088 | .370 | NI | ||||
| CRP (ng/L) | ≤3/ >3 | 0.975 | 0.461‐2.062 | .946 | NI | 1.120 | 0.512‐2.450 | .777 | NI | ||||
| CEA (ng/mL) | ≤5/ >5 | 1.312 | 0.638‐2.699 | .460 | NI | 1.487 | 0.724‐3.053 | .280 | NI | ||||
| CA19‐9 (U/ml) | ≤35/ >35 | 1.735 | 0.749‐4.021 | .199 | NI | 1.846 | 0.794‐4.291 | .155 | NI | ||||
| HBsAg | Negative/ Positive | 1.258 | 0.380‐4.164 | .707 | NI | 1.230 | 0.371‐4.082 | .735 | NI | ||||
| Group | IRE/ RFA | 2.041 | 1.009‐4.129 | .047 | 2.125 | 1.043‐4.330 | 0.038 | 2.330 | 1.138‐4.768 | .021 | 2.330 | 1.138‐4.768 | 0.021 |
| Chemotherapy type | FOLFIRINOX/ Gem | 1.084 | 0.769‐1.530 | .644 | NI | 1.014 | 0.716‐1.438 | .936 | NI | ||||
Abbreviations: ALB, albumin; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; CRP, C‐reactive protein; GGT, glutamyl transpeptidase; HBsAg, hepatitis B surface antigen; HBsAg, hepatitis B surface antigen; IBIL, indirect bilirubin; LN, lymph node metastasis; PLT, platelet count; TBIL, total bilirubin; TNM, tumor‐node‐metastasis stage; WBC, white blood cell count.